Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 12/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ERG | P11308 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21239648 | 0.82 | P2RX7 (0.48) | TACR3P2RX7 | |
| SCHEMBL8032099 | 0.82 | TACR3 (0.58) | TACR3P2RX7KCNH2ERGNPC1 | |
| SCHEMBL16291338 | 0.80 | TACR3 (0.59) | TACR3KCNH2ERGNPC1SMN1; SMN2 | |
| SCHEMBL19681420 | 0.75 | TACR3 (0.56) | TACR3KCNH2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29794109 | 0.74 | TACR3 (0.64) | TACR3P2RX7KCNH2ERGCYP1A2 | |
| SCHEMBL16291361 | 0.74 | TACR3 (0.49) | TACR3KCNH2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17644327 | 0.74 | TACR3 (0.52) | TACR3P2RX7NPC1TP53TSHR | |
| SCHEMBL930214 | 0.74 | TACR3 (0.52) | TACR3P2RX7NPC1TP53TSHR | |
| SCHEMBL14635101 | 0.74 | TACR3 (0.52) | TACR3P2RX7NPC1TP53TSHR | |
| SCHEMBL18112324 | 0.73 | TACR3 (0.57) | TACR3P2RX7KCNH2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191488-B1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-14 | — | — | EP | claimed |
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2014-12-18 | — | — | US | claimed |
| US-9993411-B2 | Dye composition using a phenol-derived coupler in a medium rich in fatty substances, processes and devices | L'OREAL (FR) | 2018-06-12 | — | — | US | disclosed |
| US-20140366284-A1 | DYE COMPOSITION USING A PHENOL-DERIVED COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESSES AND DEVICES | L'OREAL (FR) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | TACR3 12/4885P2RX7 217/4885KCNH2 236/4885 |
| US-20140366284-A1 | DYE COMPOSITION USING A PHENOL-DERIVED COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESSES AND DEVICES | F12, AKR1C3, KRT18 | TACR3 1014/4885P2RX7 3187/4885KCNH2 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.